Cutiss
Switzerland - SchlierenBiotechnology
Focus: Cutiss is a Swiss biotech company specializing in bio-engineered skin therapeutics for severe burn and wound indications. The company is a pre-revenue stage developer with a focused pipeline and Series C+ funding maturity.
Profile data last refreshed 1h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES C +
Employees
1-50
Open Jobs
0
About Cutiss
AI assessmentNot HiringNo open roles listed right now. Follow Cutiss to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
EHSG-KF
BurnsClinical Trials (1)
NCT03227146Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents
Phase 2Help build intelligence for Cutiss
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.